LEGAL DISCLAIMER: This article provides general, informational content for educational purposes only. It is not a substitute for professional legal advice from a qualified attorney. Always consult with a lawyer for guidance on your specific legal situation.
Imagine a mapmaker discovers a new, hidden island. Can they claim ownership of the island itself, forbidding anyone else from even looking at it or describing its features without paying a hefty fee? Or can they only own the unique, detailed maps they create? This is the core question behind one of the most important bioethics and patent_law cases of the 21st century: Association for Molecular Pathology v. Myriad Genetics, Inc. For years, a single company, Myriad, owned patents on two human genes—BRCA1 and BRCA2—which are strongly linked to hereditary breast and ovarian cancer. This meant they had a monopoly. They alone could perform tests on these genes, setting the price (over $3,000) and controlling all research. Patients couldn't get a second opinion. Scientists couldn't easily study the genes. This case, brought by a coalition of doctors, patients, and the aclu, challenged whether a part of the natural human body could be owned by a corporation. In 2013, the supreme_court_of_the_united_states delivered a landmark, unanimous answer that reshaped medicine, research, and our very understanding of who owns the code of life.
The story of the Myriad Genetics case doesn't begin in a courtroom, but in a laboratory during the Human Genome Project—a monumental international effort to map our entire genetic code. In the 1990s, scientists were in a race to identify specific genes linked to diseases. In 1994, a team of researchers, including some at the University of Utah and Myriad Genetics, successfully identified and sequenced the BRCA1 gene. A year later, they did the same for BRCA2. Possessing this knowledge, Myriad Genetics, in partnership with the University of Utah Research Foundation, did something that was common practice at the time: they filed for patents. They didn't just patent a method for testing the gene; they patented the “isolated” gene sequences themselves. For nearly two decades, this gave Myriad a powerful monopoly. If you were a woman with a family history of breast cancer and wanted to know if you carried the dangerous BRCA mutation, you had one option: Myriad's test. The company aggressively enforced its patents, sending cease-and-desist letters to other labs and researchers who tried to offer testing. The cost was high, and the lack of competition meant patients had no way to get a second opinion from another provider if they received a troubling result. This situation grew increasingly untenable for scientists, doctors, and patient advocates. They argued that a gene, a fundamental piece of human heredity, shouldn't be a corporate asset. In 2009, the American Civil Liberties Union (ACLU) and the Public Patent Foundation filed a lawsuit on behalf of the Association for Molecular Pathology (AMP) and a host of other plaintiffs. Their argument was simple but profound: patents on human genes were unconstitutional and violated the core principles of patent_law. The case journeyed through the lower courts with conflicting results before finally landing before the Supreme Court, setting the stage for a decision that would affect millions.
The legal fight in Myriad centered on a single, crucial section of U.S. patent law: `35_usc_101`. This statute defines what is eligible for a patent. It states that anyone who “invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent.” The courts have long interpreted this to mean there are three things you cannot patent:
This is known as the “product of nature” doctrine. You can't patent something that already exists in the wild. You can't get a patent on gold, even if you're the first person to find a huge gold deposit. However, you *could* potentially patent a new and inventive method for extracting that gold. Myriad's argument was that by “isolating” the BRCA1 and BRCA2 genes from the surrounding genetic material in the human body, they had created something “new” and distinct from what exists in nature. They claimed the isolated gene was a patentable “composition of matter.” The plaintiffs countered that isolating a gene is like taking a kidney out of a body—it's still a human kidney. The fundamental information—the genetic sequence—is identical, a product of nature, and therefore not eligible to be patented. The Supreme Court's entire decision would hinge on which of these interpretations it found more compelling.
The U.S. Supreme Court's decision sent ripples across the globe, as many countries were grappling with the same ethical and legal questions. While the Myriad ruling is binding only in the United States, its influence has been significant.
| Jurisdiction | Stance on Patenting Natural DNA | What It Means for You |
|---|---|---|
| United States | Not Patentable. The `association_for_molecular_pathology_v_myriad_genetics` ruling established that isolated but otherwise unaltered human genes are “products of nature” and cannot be patented. | In the U.S., you have access to competitive genetic testing from multiple providers for naturally occurring genes like BRCA1/2. |
| Europe | Generally Patentable (with limits). The EU's Biotechnology Directive (98/44/EC) allows for patenting isolated genes if they have a specific, disclosed industrial application. The “product of nature” bar is lower than in the U.S. | A company in Europe might still hold a patent on an isolated human gene, potentially limiting testing options or research within the EU. |
| Australia | Not Patentable. Inspired in part by the U.S. Myriad case, the High Court of Australia ruled in 2015 in *D'Arcy v Myriad Genetics Inc* that isolated nucleic acids are not patentable inventions. | Similar to the U.S., the Australian ruling promotes open access and competition for genetic diagnostic testing. |
| Canada | Not Patentable. In 2016, a Canadian Federal Court ruling in a case involving the Children's Hospital of Eastern Ontario and human genes effectively invalidated gene patents in Canada, aligning with the U.S. precedent. | The legal landscape in Canada also favors patient access over monopolistic gene patents. |
The Supreme Court's unanimous opinion, written by Justice Clarence Thomas, was a masterclass in drawing fine but critical distinctions. It didn't just give a simple “yes” or “no” but carefully dissected the science to create a new legal framework.
The Court addressed Myriad's primary claim: that by isolating the BRCA genes, they had created something patentable. The Court firmly rejected this. Justice Thomas wrote that Myriad “did not create or alter any of the genetic information encoded in the BRCA1 and BRCA2 genes.” The location and order of the nucleotides existed in nature before Myriad found them. The Court used a powerful analogy: a person who discovers a new plant in the wild cannot patent the plant itself. “Myriad's principal contribution was uncovering the precise location and genetic sequence,” the opinion states, which is a discovery, not an invention. Therefore, isolated, naturally occurring DNA is a product of nature and not patent-eligible.
This was the central battleground. Myriad's lawyers argued that the chemical act of severing the bonds to “isolate” the gene from its chromosome made it a new chemical entity. The Court disagreed. They found that this process alone did not create a “new composition of matter.” The crucial element—the information contained within the gene's sequence—remained unchanged. This part of the ruling was a huge victory for the plaintiffs and established that simply removing a natural product from its surrounding environment is not an act of invention that warrants a patent.
Here, the Court pivoted. In a laboratory, scientists can create a synthetic version of a gene called complementary DNA, or cDNA. This is done by taking the messenger RNA (mRNA) from a cell and using an enzyme to create a DNA strand from it. Crucially, this process strips out the non-coding regions of the gene (introns) that exist in natural DNA. The Supreme Court found that cDNA is patent-eligible. Why? Because the lab technician “unquestionably creates something new when cDNA is made.” An exon-only molecule is not found in nature. This distinction was vital. It allowed the Court to invalidate the patents on the natural genes that were harming patients, while still preserving a path for biotechnology companies to protect their investment in genuinely new, lab-created genetic tools and therapies. This preserved the financial incentive for innovation that the patent_system is designed to foster.
Ultimately, the Myriad Genetics case was a powerful reaffirmation of the `product_of_nature_doctrine` in the age of biotechnology. The Court drew a bright line: you cannot patent things you find in nature, but you can patent things you invent in a lab. The decision clarified that the key is whether the invention has “markedly different characteristics from any found in nature.” Isolated DNA failed this test; cDNA passed it. This principle now guides patent examiners at the `uspto` (U.S. Patent and Trademark Office) when they review applications for everything from genetic sequences to newly discovered microorganisms.
This Supreme Court decision wasn't just an abstract legal debate; it had immediate, real-world consequences for millions of people.
The most direct impact of the Myriad ruling was on patients. Before the decision, Myriad's BRCA test cost between $3,000 and $4,000. Within months of the Supreme Court's ruling, multiple companies entered the market.
For those in the biotechnology industry, the ruling provided much-needed clarity, even if it wasn't the outcome the incumbent patent-holders wanted.
The Myriad decision did not happen in a vacuum. It was the culmination of decades of legal and scientific development, standing on the shoulders of previous landmark cases.
This was the case that opened the floodgates for the biotechnology industry. Ananda Chakrabarty, a microbiologist working for General Electric, had developed a genetically engineered bacterium capable of breaking down crude oil. The `uspto` rejected his patent application on the grounds that living things could not be patented. The Supreme Court, in a 5-4 decision, disagreed. Chief Justice Burger famously wrote, “anything under the sun that is made by man” is patentable. The Court held that Chakrabarty's bacterium was not a “product of nature” but a man-made invention with “markedly different characteristics.” This case established the principle that life forms could be patented, setting the stage for patents on everything from plants to, eventually, human genes.
Just one year before Myriad, the Supreme Court decided *Mayo v. Prometheus*, a case that significantly tightened the rules for patenting medical diagnostic methods. Prometheus had patented a method for determining the proper dosage of a certain drug by observing a natural correlation in the patient's blood. The Court unanimously struck down the patent, ruling that it was essentially a patent on a law of nature. The steps involved were considered routine and not inventive enough to transform the natural law into a patent-eligible application. This decision signaled the Court's growing skepticism of patents that seemed to lock up basic scientific principles and heavily influenced the Court’s thinking in Myriad.
This case was the final act in the drama. The legal question was sharp: Is “isolated” human DNA patentable? The court's holding was equally sharp: No. But is synthetic cDNA patentable? Yes. The ruling threaded the needle, seeking to balance the need to reward true invention with the public's interest in accessing fundamental scientific knowledge. By invalidating the gene patents, the Court prevented the privatization of the human genome. By upholding cDNA patents, it ensured that the biotech industry's incentives for creating new medicines and tools remained intact. It was a pragmatic and powerful decision that immediately and profoundly impacted science, medicine, and law.
The Myriad case answered a huge question, but it also opened the door to new ones as technology continues to accelerate.
The legal and ethical debates in genetics have moved beyond simple gene sequencing.
Looking ahead, the legal framework established by Myriad will be tested by new technologies.